PubMed Health⌕ Search

Biomedical subjects

J B Malick

Publications and source records attributed to J B Malick.

45 records · Page 3Linked to original sources
PubMed1975

The evaluation of anti-parkinson drugs on reserpine-induced rigidity in rats.

The effect of anti-parkinson drugs on reserpine-induced rigidity was examined using a technique which measured rigidity by hind limb palpation. Centrally acting dopaminergic and anti-cholinergic drugs were able to antagonize reserpine-induced rigidity, whereas peripherally acting drugs had no effect. Results are discussed in terms of possible modes of action. Relative potencies of the drugs studied in this model were well correlated with the dose ranges of clinically established anti-parkinson drugs. It is concluded that measurement of reserpine-induced rigidity by hind limb palpation is a rapid and sensitive technique to evaluate potential anti-parkinson drugs.

Amantadine↗
PubMed1975

Effects of age and food deprivation on the development of muricidal behavior in rats.

The induction of muricidal behavior in the rat, under various experimental conditions, was studied in order to determine whether mouse killing is a form of predatory aggression that is closely related to feeding behavior. Rats of various ages were socially isolated and subjected to various degrees of food deprivation to determine whether the same laws that govern feeding also govern muricidal behavior. The age of the rat at the beginning of the study (8, 12 or 18 weeks of age) did not appear to significantly affect the induction of muricide by food deprivation. Chronic food deprivation caused non-killer rats to kill mice. In addition, the severity of the food deprivation influenced the induction of mouse killing such that the greater the degree of deprivation, the greater the number of rats that became killers. The effects of food deprivation on the induction of mouse killing were reversed by giving the rats access to food ad lib. Since many of the laws that govern feeding also appear to be the laws which govern mouse killing, the two behaviors may be highly inter-related.

Age Factors↗
PubMedDate not supplied

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

We evaluated the effects of ICI 204,636 in 12 hospitalized patients with schizophrenia in a double-blind, placebo-controlled, parallel-group, rising-dose study. Patients met the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised criteria for chronic or subchronic schizophrenia and had a total score > or = 30 on the 18-item Brief Psychiatric Rating Scale (BPRS) and a score > or = 3 on the Clinical Global Impression (CGI) Severity of Illness item. Patients received 21 days of double-blind treatment with increasing doses of ICI 204,636 (25 to 250 mg/d) or placebo. Efficacy was assessed using the BPRS and CGI. Response to treatment was defined as a > or = 30% decrease in the BPRS total score from baseline. Extrapyramidal symptoms and abnormal involuntary movements were assessed using the Simpson Scale and Abnormal Involuntary Movement Scale. Changes from baseline in the BPRS and CGI were significantly greater at end point for patients who received ICI 204,636 versus placebo (BPRS, -20.9 vs -4.8; CGI, -2.9 vs -1.0; P < 0.05, analysis of covariance; P < or = 0.06, Wilcoxon rank sum test). All patients in the ICI 204,636 group responded to treatment (P < 0.10) versus only two patients in the placebo group. Mild somnolence occurred in 50% of ICI 204,636-treated patients. No treatment-emergent extrapyramidal symptoms or dystonic reactions were observed. ICI 204,636 showed efficacy in the positive and negative symptoms of schizophrenia and was well tolerated.

Adolescent↗